Abstract 650P
Background
Several genomic alterations have been described in small bowel adenocarcinoma (SBA) but the prognostic value of these alterations remains unclear. The aim of this multicentre study was to determine the genomic profile of SBA and its impact on the prognosis.
Methods
Three cohorts in France and Italy were pooled. A common dataset of genomic analysis have been performed on 35 genes of interest. MSI (MicroSatellite Instable) and MMR (MisMatch Repair) status were also assessed.
Results
A total of 188 tumour samples had conclusive results for mutation analysis. The patients (pts) were male (55.3%), with duodenum primary (58.5%), stage I-II (39.6%), III (40.6%) and IV (18.8%). with a predisposing disease (21%) mainly Lynch syndrome (LS) (n=19) and Crohn disease (CD) (n=11). The most frequent mutation were KRAS (42.0%) of which 7/79 G12C, TP53 (40.4%), APC (19.1%), PIK3CA (18.6%), SMAD4 (12.8%) and ERBB2 (9.6%). TP53 mutations were more frequent in CD (81.8%) but less frequent in LS (15.8%) than in no predisposing disease (39%). ERBB2 mutations were more frequent in LS (26.3%) than in no predisposing disease (7.5%). No APC mutation was observed in CD. KRAS and SMAD4 mutations were more frequent in tumour than in localized tumour (59.4% vs 37.7%, p=0.0164) and (24.3% vs 9.9%, p=0.0187). ERBB2 mutations were less frequent in metastatic than in localized tumour (0% vs 11.9%, p=0.0272). For localized tumour univariate analysis revealed that: age ≥65 (p=0.0327), T4 (p=0.570), high grade (p=0.0028) stage III (p=0.0390) and wild type APC (p=0.395) were associated with a poor overall survival (OS). In multivariate analysis: high grade (p=0.023), age ≥65 (p=0.0123) and wild type APC (p=0.0254) were associated with a poor OS. For metastatic tumour a trend for a better OS was observed in case of a mutated KRAS tumour (HR=0.6 (0.34-1.06), p=0.0797) in univariate analysis. dMMR/MSI status was available in 238 pts. Overall, dMMR/MSI was reported in 29.8%, 31.8% in localized and 11.3% in metastatic tumour. dMMR/MSI was associated with a better OS (HR=0.61 [0.39-0.96], p=0.0333).
Conclusions
There is different genomic profile according to the predisposing disease. MSI/dMMR predict a better prognosis. APC mutation in localized and KRAS mutation in metastatic tumour are associate with a better prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Fondation ARCAD, Programme Hospitalier de Recherche Clinique.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
628P - Immunotherapy in mismatch repair-deficient metastatic colorectal cancer: Long-term outcome and novel predictive markers
Presenter: Amos Stemmer
Session: Poster session 11
629P - First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)
Presenter: David Tougeron
Session: Poster session 11
630P - Determining a prognostic score using imaging to assess the benefit of combo anti-PD1 + anti-CTL4 vs anti-PD1 in patients with metastatic MSI/dMMR colorectal cancer (mCRC MSI)
Presenter: Remy Barbe
Session: Poster session 11
631P - Using the unique somatic mutation profile of POLE loss of proof-reading mutation helps in selection of patients who may benefit from immunotherapy
Presenter: Giulia Maddalena
Session: Poster session 11
632P - Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab
Presenter: Sebastian Meltzer
Session: Poster session 11
633P - Genomic alterations in SPEN predict outcome of immune checkpoint therapy in gastrointestinal cancer
Presenter: Changxiong Wu
Session: Poster session 11
634P - The ave-rec phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for resectable ESMO high risk rectal cancers
Presenter: Michael Michael
Session: Poster session 11
635P - Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study
Presenter: Marc van den Eynde
Session: Poster session 11